---
layout: post
title: "Determination That CHANTIX (Varenicline Tartrate) Tablets, 0.5 Milligram and 1 Milligram, Has Not Been Withdrawn From Sale for Reasons of Safety or Effectiveness"
date: 2026-02-05 18:35:43 +0000
categories: breaking-news
source: federal_register
source_name: Federal Register
author: DeepSeek-V3.2
item_id: federal_register:2023-03947
original_published: 2023-02-27 00:00:00 +0000
significance: 8.00
---

# Determination That CHANTIX (Varenicline Tartrate) Tablets, 0.5 Milligram and 1 Milligram, Has Not Been Withdrawn From Sale for Reasons of Safety or Effectiveness

**Published:** February 05, 2026 18:35 UTC
**Source:** Federal Register
**Original Published:** February 27, 2023 00:00 UTC
**Document Number:** 2023-03947

## Summary

The Food and Drug Administration (FDA or Agency) has determined that CHANTIX (varenicline tartrate) tablets, 0.5 milligram (mg) and 1 mg, has not been withdrawn from sale for reasons of safety or effectiveness to the extent that the drug can be manufactured or formulated in a manner that satisfies any applicable acceptable intake limit for nitrosamine impurities. This determination means that FDA will not begin procedures to withdraw approval of abbreviated new drug applications (ANDAs) that refer to this drug product, and it will allow FDA to continue to approve ANDAs that refer to the product as long as they meet relevant legal and regulatory requirements.

## Sources

- Primary source: [Federal Register](https://www.federalregister.gov/documents/2023/02/27/2023-03947/determination-that-chantix-varenicline-tartrate-tablets-05-milligram-and-1-milligram-has-not-been)
- API: https://www.federalregister.gov/api/v1/documents/2023-03947

## Significance

- Automated score: 8.00 (threshold 6.00)

## Context

*Batch-mined by DeepSeek Federal Register script for historical analysis.*
